Haleon plc (HLN)
- Previous Close
8.40 - Open
8.38 - Bid 8.30 x 29200
- Ask 8.50 x 3000
- Day's Range
8.38 - 8.48 - 52 Week Range
7.70 - 8.98 - Volume
2,873,301 - Avg. Volume
5,658,214 - Market Cap (intraday)
38.584B - Beta (5Y Monthly) --
- PE Ratio (TTM)
30.18 - EPS (TTM)
0.28 - Earnings Date --
- Forward Dividend & Yield 0.21 (2.52%)
- Ex-Dividend Date Mar 14, 2024
- 1y Target Est
9.65
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
www.haleon.com25,408
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: HLN
Performance Overview: HLN
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HLN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HLN
Valuation Measures
Market Cap
38.20B
Enterprise Value
48.78B
Trailing P/E
30.01
Forward P/E
18.83
PEG Ratio (5yr expected)
1.73
Price/Sales (ttm)
2.78
Price/Book (mrq)
1.86
Enterprise Value/Revenue
4.32
Enterprise Value/EBITDA
20.75
Financial Highlights
Profitability and Income Statement
Profit Margin
9.28%
Return on Assets (ttm)
4.28%
Return on Equity (ttm)
6.70%
Revenue (ttm)
11.3B
Net Income Avi to Common (ttm)
1.05B
Diluted EPS (ttm)
0.28
Balance Sheet and Cash Flow
Total Cash (mrq)
1.04B
Total Debt/Equity (mrq)
57.42%
Levered Free Cash Flow (ttm)
1.17B
Research Analysis: HLN
Company Insights: HLN
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: HLN
Analyst Report: Haleon plc
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon’s brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
RatingPrice TargetAnalyst Report: Haleon plc
Haleon is a pure-play consumer healthcare company focusing on oral health, respiratory health, pain relief, vitamins, supplements, and digestive health across 170 markets. Its products include consumer staples as well as over-the-counter medicines. Haleon was incorporated in 2021 and is headquartered in Brentford, UK.
RatingPrice TargetMarket Digest: ACM, AES, HLN
As stocks keep trending higher, insiders continue to exercise restraint. While their defensive posture has stabilized (and indeed lessened a tad) over the past few weeks, it seems that corporate executives, directors and beneficial owners view overall stock valuations as likely extended. That attitude appears to be mirrored in the broader market. Investors are clearly willing to push share prices higher, but the selling days (when they do occur) tend to involve noticeable drops -- suggesting a readiness to withdraw quickly if (if) any bad news has legs. So far, though, that just hasn't been the case, with big down days turning out to be one-day wonders.
Analyst Report: Haleon plc
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon’s brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
RatingPrice Target